For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Interleukin-17 (IL-17), a pro-inflammatory cytokine produced in large amounts exclusively by T cells, is part of a family of at least six members (IL-17 A to F) of the IL-17 family. IL-17A is a glycosylated homodimeric protein composed of two 133 amino acid A chains bound by two disulfide bonds. It acts on fibroblasts and macrophages by binding to its receptors to induce the secretion of other pro-inflammatory mediators such as TNF-?, IL-1?, IL-6, IL-8. IL-17 plays critical roles in autoimmune conditions such as lupus erythematosus, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, and inflammatory skin diseases. As such, inhibitors have been developed as possible treatments for many of these diseases. IL-17 is also a target for anti-inflammatory therapies to improve recovery post-stroke and to reduce the development of skin cancer. The present kit permits the detection of mouse IL-17A homodimer (i.e. analyte) in mouse serum, plasma, and cell culture supernatants.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.